On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

The successful commercialization of acoramidis could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability. BridgeBio's valuation relies on the ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...